A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

NCT05139719 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

Interventions

DRUG: HEC585 dose A
DRUG: HEC585 dose B
DRUG: Placebo

Sponsor

Sunshine Lake Pharma Co., Ltd.